Snacking has long been driven by habit, impulse, and comfort. For decades, salty snacks, chocolates, biscuits, and baked foods benefited from almost automatic demand. However, the rapid adoption of GLP-1 weight loss drugs is beginning to challenge this foundation. According to multiple studies, these medications significantly reduce appetite, cravings, and overall food intake — directly impacting snack sales.
From the perspective of a market research firm, this shift represents more than a short-term volume dip. It signals a structural change in how consumers engage with food. Research shows GLP-1 users are spending less on snacks, processed foods, and fast food, while gravitating toward fruits, leafy greens, and water. The psychological trigger behind snacking — craving — is being weakened.
This is already visible in financial results. Major snack brands have reported declining volumes in North America, the world’s largest snacking market. While inflation and pricing pressures play a role, GLP-1 adoption is emerging as a critical underlying factor. As usage expands beyond early adopters, the impact will only deepen.
Actionable insights suggest that “less but better” will define the future of food. Portion-controlled, nutrient-dense snacks with high protein or fiber content are better positioned to stay relevant. Traditional indulgent snacks, if unchanged, face sharper disruption.
For snack manufacturers, the opportunity lies in adaptation. Brands that use consumer insights to reformulate products, resize portions, and reposition snacks as functional or better-for-you options can still capture value. The winners will not be those who deny the shift, but those who redesign their portfolios around changing biology, not just changing tastes.